SciCombinator

Discover the most talked about and latest scientific content & concepts.

Abstract
A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.
Tweets*
63
Facebook likes*
1
Reddit*
0
News coverage*
2
Blogs*
3
SC clicks
2
Concepts
Osteoclast, Ciliary neurotrophic factor, Immune system, Interleukin, Interleukin-6 receptor, Tocilizumab, Interleukin 6, Rheumatoid arthritis
MeSH headings
Antibodies, Monoclonal, Humanized, Coronary Disease, Gene Frequency, Genetic Association Studies, Genetic Variation, Genotype, Humans, Inflammation Mediators, Mendelian Randomization Analysis, Phenotype, Polymorphism, Single Nucleotide, Randomized Controlled Trials as Topic, Receptors, Interleukin-6, Signal Transduction, Treatment Outcome
comments powered by Disqus

* Data courtesy of Altmetric.com